{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG" in comments (approximate match)
Status:
US Previously Marketed
First marketed in 1921
Class:
PROTEIN
Status:
US Previously Marketed
First marketed in 1921
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125795
(2023)
Source URL:
First approved in 2023
Source:
BLA125795
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125771
(2023)
Source URL:
First approved in 2023
Source:
BLA125771
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
GOHIBIC by InflaRx GmbH
(2023)
Source URL:
First approved in 2023
Source:
GOHIBIC by InflaRx GmbH
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125659
(2021)
Source URL:
First approved in 2021
Source:
BLA125659
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA761158
(2020)
Source URL:
First approved in 2020
Source:
BLA761158
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2017)
Source URL:
First approved in 2017
Source:
21 CFR 347
Source URL:
Class:
PROTEIN
